Yitian Lang
Huangpu Branch
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations: a cost-utility analysis.
Journal: Frontiers in pharmacology
Published: June 02, 2026
Cost-effectiveness analysis of trastuzumab deruxtecan versus ramucirumab plus paclitaxel as second-line treatment for HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
Journal: Frontiers in pharmacology
Published: February 14, 2026
Immune checkpoint blockers plus chemotherapy as the first-line treatment for advanced or metastatic squamous non-small-cell lung carcinoma: a network meta-analysis and economic evaluation.
Journal: Frontiers in pharmacology
Published: July 21, 2025
Cost-effectiveness analysis of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy for advanced HER2-negative gastric or gastro-esophageal junction cancer.
Journal: Therapeutic advances in gastroenterology
Published: January 20, 2025
Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis.
Journal: Frontiers in pharmacology
Published: September 12, 2024
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis.
Journal: Clinical rheumatology
Published: March 07, 2023
Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost-effectiveness analysis.
Journal: Cancer medicine
Published: October 11, 2022
Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States.
Journal: Breast cancer (Dove Medical Press)
Published: September 13, 2022
Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Journal: Clinical drug investigation
Published: August 29, 2022
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: July 19, 2022
Last Updated: 09/26/2026